Lonza | LONN - Equity Capital And Reserves


Lonza reported CHF9.13B in Equity Capital and Reserves for its fiscal semester ending in December of 2025.





Equity Capital And Reserves Change Date
Akzo Nobel EUR 4.85B 28M Jun/2026
Alcon AG USD 22.13B 99M Mar/2026
Almirall EUR 1.53B 43.26M Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
BASF EUR 36.32B 846M Jun/2026
Bayer EUR 28.85B 2.9B Mar/2026
Beiersdorf EUR 8.6B 133M Dec/2025
Covestro EUR 7B 908M Dec/2025
Demant DKK 9.84B 446M Dec/2025
Fresenius EUR 19.7B 766M Jun/2026
Fresenius Medical Care EUR 14.2B 13.95B Mar/2026
Geberit CHF 1.54B 237.4M Mar/2025
Genmab DKK 5.96B 275M Jun/2026
Givaudan CHF 4.54B 430M Dec/2025
GlaxoSmithKline GBP 17.64B 223M Jun/2026
GN Store Nord DKK 10.12B 4.76B Mar/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Johnson Matthey GBP 2.02B 85M Jun/2026
Merck EUR 29.74B 1.15B Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Philips EUR 11.48B 84M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Sika AG CHF 6.66B 481.4M Dec/2025
Smith & Nephew USD 5.18B 356M Jun/2026
Solvay EUR 1.11B 70M Jun/2026
UCB EUR 10.87B 1.18B Dec/2025